Janssen Pharmaceuticals Says New Phase 3 Tremfya Results In Ulcerative Colitis Show 77% Overall Clinical Response Rate And Early Symptom Improvement
Portfolio Pulse from Benzinga Newsdesk
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (JNJ), has announced new Phase 3 results for Tremfya in Ulcerative Colitis, showing a 77% overall clinical response rate and early symptom improvement.
October 23, 2023 | 7:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, has reported positive Phase 3 results for Tremfya in Ulcerative Colitis. This could potentially boost JNJ's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, potentially driving up the stock price. Given that Janssen is a subsidiary of JNJ, this news is highly relevant and could have a significant impact on JNJ's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100